Although ICI-based therapies, primarily represented by PD-1/PD-L1 inhibitors, significantly improve the overall survival in R/M NPC patients, only a few of NPC patients can achieve long-term benefits. This evidence concerns the gene CD274 and nasopharyngeal carcinoma.